Charles Schwab Investment Management Inc. Grows Position in Zura Bio Limited (NASDAQ:ZURA)

Charles Schwab Investment Management Inc. raised its position in shares of Zura Bio Limited (NASDAQ:ZURA) by 51.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 291,807 shares of the company’s stock after acquiring an additional 98,972 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.43% of Zura Bio worth $1,185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Point72 Asset Management L.P. purchased a new stake in Zura Bio during the second quarter valued at $8,446,000. Armistice Capital LLC raised its position in shares of Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after buying an additional 876,000 shares in the last quarter. Great Point Partners LLC raised its position in shares of Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after buying an additional 1,884,501 shares in the last quarter. Forefront Analytics LLC lifted its holdings in shares of Zura Bio by 22.1% in the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in Zura Bio in the second quarter worth about $43,000. 61.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZURA has been the subject of several analyst reports. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Zura Bio in a research note on Monday, November 18th. Chardan Capital lowered their price target on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Piper Sandler restated an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $15.80.

Zura Bio Price Performance

Zura Bio stock opened at $2.51 on Wednesday. The firm has a 50-day moving average of $3.69 and a two-hundred day moving average of $3.74. Zura Bio Limited has a 1 year low of $2.00 and a 1 year high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Equities analysts forecast that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 22.10% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.